IdorsiaXSWX:IDIA +2.56%49 OCF Yield % is -8.23 as of Jun. 26, 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 49/100 and a GF Value™ of CHF2.85 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Idorsia ranks better than 50.39% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Idorsia OCF Yield % Related Terms
Idorsia OCF Yield % Historical Data
* Premium members only.
The historical data trend for Idorsia's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Idorsia's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Idorsia's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a OCF Yield % of -8.23 as of Jun. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #704 out of 1419 companies in the Biotechnology industry, placing it in the top 49.6%.
Is Idorsia's OCF Yield % too high?
Idorsia's current OCF Yield % is -8.23. Based on the distribution chart, Idorsia ranks #704 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Idorsia has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #704 out of 1419 companies for OCF Yield %. This puts Idorsia in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Idorsia and its competitors. Idorsia's current OCF Yield % is -8.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.85, compared to a current price of CHF6.02 — trading 111.2% above its estimated fair value. The current OCF Yield % is -8.23. Idorsia's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current OCF Yield % is -8.23 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.02 is trading 111.2% above its estimated GF Value™ of CHF2.85.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
OCF Yield %: -8.23
GF Value™: CHF2.85 vs. price of CHF6.02 (111.2% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
49GF Score
Get the complete analysis for XSWX:IDIA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
